Amendment: SEC Form SC 13G/A filed by Eagle Pharmaceuticals Inc.

$EGRX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $EGRX alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $EGRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EGRX

DatePrice TargetRatingAnalyst
8/10/2023$26.00 → $17.00Neutral → Underweight
Piper Sandler
8/9/2023$26.00 → $17.00Neutral → Underweight
Piper Sandler
More analyst ratings

$EGRX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

    WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the "Company" or "Eagle") today announced that it has notified The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to file its own Form 25 (Notification of Removal of Listing) with the U.S. Securities and Exchange Commission (the "SEC") to complete the previously-disclosed process to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Market in advance of Nasdaq's anticipated filing of a Form 25 with the SEC. As previously disclosed, the Common Stock was suspended from trading on Nasdaq as of October 3, 2024, pursuant to

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

    WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EGRX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EGRX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EGRX
SEC Filings

See more

$EGRX
Leadership Updates

Live Leadership Updates

See more
  • Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer

    WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTC:EGRX) (the "Company" or "Eagle") today announced the appointment of Christopher Krawtschuk as Chief Financial Officer ("CFO") of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk's appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company's board of directors. "Chris is a talented finance executive with deep experience in the pharmaceutical sector, and we are pleased to welcome him to the Eagle team," said Michael Graves, Interim Principal Executive Officer of Eagle Pharmaceuticals. "His experienc

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

    WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. "We are very pleased with our acquisition of Acacia Pharma Group Plc ("Acacia") and its two commercial products, BARHEMSYS® and BYFAVO®. As we commenced their integration, we continued to be impressed with Acacia Pharma's previous plans and positioning of the products. It is our belief that the two products were underinvested, both from a cost and manpower perspective. Additionally, the products were launched into a very difficult COVID environment, in which access to d

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced the appointment of Luciana ("Lu") Borio, MD, to its Board of Directors. Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration ("FDA" or "Agency"). "We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world's most complex challenges. Her

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EGRX
Financials

Live finance-specific insights

See more
  • Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

    WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the "Company" or "Eagle") (OTC:EGRX) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights agreement (the "Rights Plan"), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company's stockholders to have the opportunity to realize the long-term value of their investment. The Rights Plan is intended to reduce the likelihood that any person or group gains control of the Company through open market accumulation of the Company's com

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Eagle Delays Third Quarter 2023 Results and Conference Call

    WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023

    WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTimeToll free (U.S.)InternationalThursday, November 9, 2023 8:30 a.m. ET800-343-4136203-518-9843  Webcast (live and replay)www.eagleus.com, under the "Investor Relations" section   A replay of the conference call will be available for two weeks after the ca

    $EGRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EGRX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more